December 27, 2017 / 2:10 PM / 6 months ago

BRIEF-Actinium Pharmaceuticals Provides Update On Pivotal Phase 3 Trial Of Iomab-B

* ACTINIUM PHARMACEUTICALS PROVIDES UPDATE ON PIVOTAL PHASE 3 TRIAL OF IOMAB-B: INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS SIERRA TRIAL CONTINUE

* ACTINIUM PHARMACEUTICALS INC - CONFIDENT THAT CO WILL BE ABLE TO COMPLETE PATIENT ENROLLMENT BY END OF 2018

* ACTINIUM PHARMACEUTICALS - INDEPENDENT DATA MONITORING COMMITTEE FOR PIVOTAL PHASE 3 SIERRA TRIAL OF IOMAB-B COMPLETED REVIEW OF DATA FROM TRIAL

* ACTINIUM PHARMACEUTICALS - WILL AMEND PROTOCOL OF SIERRA TRIAL TO EXPAND SALVAGE CHEMOTHERAPY REGIMENS AVAILABLE IN CONTROL ARM OF STUDY

* ACTINIUM PHARMACEUTICALS - SUPPLIED DOSIMETRIC & THERAPEUTIC DOSES TO PATIENTS IN STUDY ARM & THOSE THAT CROSSED OVER TO IOMAB-B ARM FROM CONTROL ARM

* ACTINIUM PHARMA -PATIENTS THAT CROSS OVER FROM CONTROL ARM COUNTED AS FAILURES FOR PRIMARY ENDPOINT OF DURABLE COMPLETE REMISSION OF AT LEAST 6 MONTHS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below